Four studies reported still birth outcomes in pregnant women with IBD, and the pooled OR was 0.85 (95% CI, 0.55–1.33; P = 0.48) when patients treated with anti-TNF-α therapy (n = 4605) were compared with disease-matched controls (n = 23,860) (Fig. 2). This evidence concerns the gene TNF and inflammatory bowel disease.